Literature DB >> 18155846

Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function.

S Lesné1, L Kotilinek, K H Ashe.   

Abstract

The amyloid-beta (Abeta) protein exists in the aging mammalian brain in diverse assembly states, including amyloid plaques and soluble Abeta oligomers. Both forms of Abeta have been shown to impair neuronal function, but their precise roles in Alzheimer's disease (AD) -associated memory loss remain unclear. Both types of Abeta are usually present at the same time in the brain, which has made it difficult to evaluate the effects of plaques and oligomers individually on memory function. Recently, a particular oligomeric Abeta assembly, Abeta 56, was found to impair memory function in the absence of amyloid plaques. Until now it has not been possible to determine the effects of plaques, in the absence of Abeta oligomers, on memory function. We have identified Tg2576 mice with plaques but markedly reduced levels of Abeta oligomers, which enabled us to study the effects of plaques alone on memory function. We found that animals with amyloid plaques have normal memory function throughout an episode of reduced Abeta oligomers, which occurs during a period of accelerated amyloid plaque formation. These observations support the importance of Abeta oligomers in memory loss and indicate that, at least initially, amyloid plaques do not impair memory.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18155846      PMCID: PMC2677385          DOI: 10.1016/j.neuroscience.2007.10.054

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  20 in total

Review 1.  Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

Authors:  W L Klein; G A Krafft; C E Finch
Journal:  Trends Neurosci       Date:  2001-04       Impact factor: 13.837

2.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

3.  Extended analysis of path data from mutant mice using the public domain software Wintrack.

Authors:  D P Wolfer; R Madani; P Valenti; H P Lipp
Journal:  Physiol Behav       Date:  2001-08

4.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

5.  The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Marcus A Westerman; Deirdre Cooper-Blacketer; Ami Mariash; Linda Kotilinek; Takeshi Kawarabayashi; Linda H Younkin; George A Carlson; Steven G Younkin; Karen H Ashe
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

6.  Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease.

Authors:  B Urbanc; L Cruz; R Le; J Sanders; K Hsiao Ashe; K Duff; H E Stanley; M C Irizarry; B T Hyman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-09       Impact factor: 11.205

7.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

Review 8.  Learning and memory in transgenic mice modeling Alzheimer's disease.

Authors:  K H Ashe
Journal:  Learn Mem       Date:  2001 Nov-Dec       Impact factor: 2.460

9.  Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway.

Authors:  Ganesh M Shankar; Brenda L Bloodgood; Matthew Townsend; Dominic M Walsh; Dennis J Selkoe; Bernardo L Sabatini
Journal:  J Neurosci       Date:  2007-03-14       Impact factor: 6.167

10.  Reversible memory loss in a mouse transgenic model of Alzheimer's disease.

Authors:  Linda A Kotilinek; Brian Bacskai; Marcus Westerman; Takeshi Kawarabayashi; Linda Younkin; Bradley T Hyman; Steven Younkin; Karen H Ashe
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

View more
  69 in total

1.  Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease.

Authors:  Gaëlle Naert; Serge Rivest
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

Review 2.  Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants.

Authors:  Richard Mayeux; Nicole Schupf
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

Review 3.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 4.  Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology.

Authors:  Daniel J Glass; Steven E Arnold
Journal:  Alzheimers Dement       Date:  2011-12-03       Impact factor: 21.566

5.  Aβ aggregation profiles and shifts in APP processing favor amyloidogenesis in canines.

Authors:  Viorela Pop; Elizabeth Head; Nicole C Berchtold; Charles G Glabe; Christa M Studzinski; Adam M Weidner; M Paul Murphy; Carl W Cotman
Journal:  Neurobiol Aging       Date:  2010-04-30       Impact factor: 4.673

Review 6.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

7.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

8.  Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.

Authors:  Reisa A Sperling; Keith A Johnson; P Murali Doraiswamy; Eric M Reiman; Adam S Fleisher; Marwan N Sabbagh; Carl H Sadowsky; Alan Carpenter; Mat D Davis; Ming Lu; Matthew Flitter; Abhinay D Joshi; Christopher M Clark; Michael Grundman; Mark A Mintun; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  Neurobiol Aging       Date:  2012-08-09       Impact factor: 4.673

9.  Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.

Authors:  Mathew A Sherman; Michael LaCroix; Fatou Amar; Megan E Larson; Colleen Forster; Adriano Aguzzi; David A Bennett; Martin Ramsden; Sylvain E Lesné
Journal:  J Neurosci       Date:  2016-09-14       Impact factor: 6.167

10.  Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis.

Authors:  Sami J Barmada; Gaia Skibinski; Erica Korb; Elizabeth J Rao; Jane Y Wu; Steven Finkbeiner
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.